Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner

Basic Research in Cardiology

Volumn 106, Issue 3, 2011, Pages 431-446

  Birnbaum, Yochai ^a,b,c   Long, Bo ^a   Qian, Jinqiao ^a,d   Perez Polo, Jose R ^a   Ye, Yumei ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Cyclooxygenase 2; Cytosolic phospholipase A 2; Infarction; Ischemia; PPAR ; Reperfusion

Indexed keywords

CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN KINASE B; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HEART CELL CULTURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY; UPREGULATION;

ANIMALS; CYCLOOXYGENASE 2; ENZYME ACTIVATION; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHOLIPASES A2, CYTOSOLIC; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 79955549851     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-011-0162-3     Document Type: Article

References (66)

1. M Artwohl C Furnsinn W Waldhausl T Holzenbein G Rainer A Freudenthaler M Roden SM Baumgartner-Parzer 2005 Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism Diabetologia 48 586 594 10.1007/s00125-005-1672-z 15729575 10.1007/s00125-005- 1672-z 1:CAS:528:DC%2BD2MXisVCitb4%3D (Pubitemid 40487307)
2. S Atar Y Ye Y Lin SY Freeberg SP Nishi S Rosanio MH Huang BF Uretsky JR Perez-Polo Y Birnbaum 2006 Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2 Am J Physiol Heart Circ Physiol 290 H1960 H1968 10.1152/ajpheart.01137.2005 16339820 10.1152/ajpheart.01137.2005 1:CAS:528:DC%2BD28XkvFSmsbc%3D
3. Y Birnbaum Y Lin Y Ye JD Martinez MH Huang CY Lui JR Perez-Polo BF Uretsky 2007 Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin Am J Physiol Heart Circ Physiol 292 H2891 H2897 10.1152/ajpheart.01269.2006 17277020 10.1152/ajpheart.01269.2006 1:CAS:528:DC%2BD2sXmvF2ksr4%3D (Pubitemid 47084538)
4. Y Birnbaum Y Ye Y Lin SY Freeberg SP Nishi JD Martinez MH Huang BF Uretsky JR Perez-Polo 2006 Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat Circulation 114 929 935 10.1161/CIRCULATIONAHA.106.629907 16908763 10.1161/CIRCULATIONAHA.106. 629907 1:CAS:528:DC%2BD28Xotlaitb4%3D (Pubitemid 44337136)
5. Y Birnbaum Y Ye S Rosanio S Tavackoli ZY Hu ER Schwarz BF Uretsky 2005 Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury Cardiovasc Res 65 345 355 10.1016/j.cardiores.2004. 10.018 15639473 10.1016/j.cardiores.2004.10.018 1:CAS:528:DC%2BD2MXitVamtg%3D%3D (Pubitemid 40082476)
6. F Biscetti G Straface V Arena E Stigliano G Pecorini P Rizzo G De Angelis L Iuliano G Ghirlanda A Flex 2009 Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation Cardiovasc Diabetol 8 49 10.1186/1475-2840-8-49 19737384 10.1186/1475-2840-8-49
7. K Boengler I Konietzka A Buechert Y Heinen D Garcia-Dorado G Heusch R Schulz 2007 Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43 Am J Physiol Heart Circ Physiol 292 H1764 H1769 10.1152/ajpheart. 01071.2006 17142336 10.1152/ajpheart.01071.2006 1:CAS:528:DC%2BD2sXks1Kju7c%3D (Pubitemid 46572399)
8. R Bolli K Shinmura XL Tang E Kodani YT Xuan Y Guo B Dawn 2002 Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning Cardiovasc Res 55 506 519 10.1016/S0008-6363(02)00414-5 12160947 10.1016/S0008-6363(02)00414-5 1:CAS:528:DC%2BD38XlvVWnsr8%3D (Pubitemid 34874945)
9. O Bouhidel S Pons R Souktani R Zini A Berdeaux B Ghaleh 2008 Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice Am J Physiol Heart Circ Physiol 295 H1580 H1586 10.1152/ajpheart.00379.2008 18689499 10.1152/ajpheart.00379.2008 1:CAS:528:DC%2BD1cXht1ymur7K
10. B Brunmair F Gras S Neschen M Roden L Wagner W Waldhausl C Furnsinn 2001 Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression Diabetes 50 2309 2315 10.2337/diabetes.50.10.2309 11574413 10.2337/diabetes.50.10.2309 1:CAS:528:DC%2BD3MXntlGhu70%3D (Pubitemid 33641916)
11. AA Bulhak C Jung CG Ostenson JO Lundberg PO Sjoquist J Pernow 2009 PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway Am J Physiol Heart Circ Physiol 296 H719 H727 10.1152/ajpheart.00394.2008 19151258 10.1152/ajpheart.00394.2008 1:CAS:528:DC%2BD1MXjtFGksLo%3D
12. RA Derlacz K Hyc M Usarek AK Jagielski J Drozak R Jarzyna 2008 PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules Biochem Cell Biol 86 396 404 10.1139/o08-105 18923541 10.1139/O08-105 1:CAS:528:DC%2BD1cXht1aqsLvN
13. JA Dormandy B Charbonnel DJ Eckland E Erdmann M Massi-Benedetti IK Moules AM Skene MH Tan PJ Lefebvre GD Murray E Standl RG Wilcox L Wilhelmsen J Betteridge K Birkeland A Golay RJ Heine L Koranyi M Laakso M Mokan A Norkus V Pirags T Podar A Scheen W Scherbaum G Schernthaner O Schmitz J Skrha U Smith J Taton 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279 1289 10.1016/S0140-6736(05)67528-9 16214598 10.1016/S0140-6736(05)67528-9 1:CAS:528:DC%2BD2MXhtVOlu7fO (Pubitemid 41416583)
14. SZ Duan CY Ivashchenko MW Russell DS Milstone RM Mortensen 2005 Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice Circ Res 97 372 379 10.1161/01.RES.0000179226.34112.6d 16051889 10.1161/01.RES.0000179226.34112.6d 1:CAS:528:DC%2BD2MXntlSiurg%3D (Pubitemid 41216142)
15. Z Ebrahim DM Yellon GF Baxter 2007 Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension Exp Gerontol 42 807 814 10.1016/j.exger.2007.04.005 17532161 10.1016/j.exger.2007.04.005 1:CAS:528:DC%2BD2sXotVWlsrk%3D (Pubitemid 47058862)
16. WJ Fan D van Vuuren S Genade A Lochner 2010 Kinases and phosphatases in ischaemic preconditioning: a re-evaluation Basic Res Cardiol 105 495 511 10.1007/s00395-010-0086-3 20127248 10.1007/s00395-010-0086-3 1:CAS:528:DC%2BC3cXlsFGrs74%3D
17. A Galli E Ceni DW Crabb T Mello R Salzano C Grappone S Milani E Surrenti C Surrenti A Casini 2004 Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms Gut 53 1688 1697 10.1136/gut.2003.031997 15479693 10.1136/gut.2003.031997 1:CAS:528: DC%2BD2cXhtVajtrjM (Pubitemid 39434116)
18. T Glatz I Stock M Nguyen-Ngoc P Gohlke T Herdegen J Culman Y Zhao 2010 Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator- activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain J Hypertens 28 1488 1497 10.1097/HJH.0b013e3283396e4e 20410836 10.1097/HJH.0b013e3283396e4e 1:CAS:528:DC%2BC3cXnvFWktro%3D
19. AT Gonon A Bulhak F Labruto PO Sjoquist J Pernow 2007 Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide Basic Res Cardiol 102 80 89 10.1007/s00395-006-0613-4 16900441 10.1007/s00395-006-0613-4 1:CAS:528:DC%2BD2sXhvFymu7Y%3D (Pubitemid 44932773)
20. P Gres R Schulz J Jansen C Umschlag G Heusch 2002 Involvement of endogenous prostaglandins in ischemic preconditioning in pigs Cardiovasc Res 55 626 632 12160960 10.1016/S0008-6363(01)00505-3 1:CAS:528:DC%2BD38XlvVWnsb8%3D (Pubitemid 34874957)
21. JK Han HS Lee HM Yang J Hur SI Jun JY Kim CH Cho GY Koh JM Peters KW Park HJ Cho HY Lee HJ Kang BH Oh YB Park HS Kim 2008 Peroxisome proliferator- activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway Circulation 118 1021 1033 10.1161/CIRCULATIONAHA.108.777169 18711014 10.1161/CIRCULATIONAHA.108.777169 1:CAS:528:DC%2BD1cXhtVejsL3K
22. DJ Hausenloy 2009 Signalling pathways in ischaemic postconditioning Thromb Haemost 101 626 634 10.1160/TH08-11-0734 19350104 1:CAS:528: DC%2BD1MXltVertLw%3D
23. DJ Hausenloy G Baxter R Bell HE Botker SM Davidson J Downey G Heusch M Kitakaze S Lecour R Mentzer MM Mocanu M Ovize R Schulz R Shannon M Walker G Walkinshaw DM Yellon 2010 Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations Basic Res Cardiol 105 677 686 10.1007/s00395-010-0121-4 20865418 10.1007/s00395-010-0121-4
24. DJ Hausenloy A Tsang DM Yellon 2005 The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning Trends Cardiovasc Med 15 69 75 10.1016/j.tcm.2005.03.001 15885573 10.1016/j.tcm.2005.03.001 1:CAS:528:DC%2BD2MXktVOisLw%3D (Pubitemid 40693390)
25. DJ Hausenloy DM Yellon 2006 Survival kinases in ischemic preconditioning and postconditioning Cardiovasc Res 70 240 253 10.1016/j.cardiores.2006.01.017 16545352 10.1016/j.cardiores.2006.01.017 1:CAS:528:DC%2BD28XjvVGjurs%3D
26. G Heusch 2009 No risk, no cardioprotection? A critical perspective Cardiovasc Res 84 173 175 10.1093/cvr/cvp298 19713282 10.1093/cvr/cvp298 1:CAS:528:DC%2BD1MXht1OrtLvK
27. G Heusch K Boengler R Schulz 2008 Cardioprotection: nitric oxide, protein kinases, and mitochondria Circulation 118 1915 1919 10.1161/CIRCULATIONAHA.108. 805242 18981312 10.1161/CIRCULATIONAHA.108.805242
28. S Hinrichs J Heger R Schreckenberg S Wenzel G Euler C Arens M Bader S Rosenkranz E Caglayan KD Schluter 2011 Controlling cardiomyocyte length: the role of renin and PPAR-{gamma} Cardiovasc Res 89 344 352 10.1093/cvr/cvq313 20884641 10.1093/cvr/cvq313 1:CAS:528:DC%2BC3MXnsVWhtw%3D%3D
29. PD Home SJ Pocock H Beck-Nielsen PS Curtis R Gomis M Hanefeld NP Jones M Komajda JJ McMurray 2009 Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2125 2135 10.1016/S0140-6736(09)60953-3 19501900 10.1016/S0140-6736(09)60953-3 1:CAS:528:DC%2BD1MXnsFSis78%3D
30. SH Ihm K Chang HY Kim SH Baek HJ Youn KB Seung JH Kim 2010 Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor Basic Res Cardiol 105 399 407 10.1007/s00395-009-0071-x 19902320 10.1007/s00395-009-0071-x 1:CAS:528:DC%2BC3cXis1yhsLY%3D
31. H Ito A Nakano M Kinoshita A Matsumori 2003 Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Lab Invest 83 1715 1721 10.1097/01.LAB.0000106724.29121.DA 14691289 10.1097/01.LAB.0000106724.29121.DA 1:CAS:528:DC%2BD3sXpsl2msL8%3D (Pubitemid 38018534)
32. KT Keyes J Xu B Long C Zhang Z Hu Y Ye 2010 Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction Am J Physiol Heart Circ Physiol 298 H1198 H1208 10.1152/ajpheart.00915.2009 20097771 10.1152/ajpheart.00915.2009 1:CAS:528:DC%2BC3cXkvVSjsLY%3D
33. SF Kim DA Huri SH Snyder 2005 Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2 Science 310 1966 1970 10.1126/science.1119407 16373578 10.1126/science.1119407 1:CAS:528: DC%2BD2MXhtlagurvK (Pubitemid 43005992)
34. S Lecour 2009 Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47 32 40 10.1016/j.yjmcc.2009.03.019 19344728 10.1016/j.yjmcc.2009.03.019 1:CAS:528:DC%2BD1MXms1Ortrw%3D
35. CH Lee P Olson RM Evans 2003 Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors Endocrinology 144 2201 2207 10.1210/en.2003-0288 12746275 10.1210/en.2003-0288 1:CAS:528: DC%2BD3sXktFehtL4%3D (Pubitemid 36629867)
36. AM Lennon M Ramauge A Dessouroux M Pierre 2002 MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species J Biol Chem 277 29681 29685 10.1074/jbc.M201517200 12052825 10.1074/jbc.M201517200 1:CAS:528:DC%2BD38XmsVKitbg%3D
37. AM Lincoff K Wolski SJ Nicholls SE Nissen 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 10.1001/jama.298.10.1180 17848652 10.1001/jama.298.10.1180 1:CAS:528:DC%2BD2sXhtVGmtL3J (Pubitemid 47403104)
38. HB Liu YS Hu RL Medcalf RW Simpson AE Dear 2005 Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation Biochem Biophys Res Commun 334 30 37 10.1016/j.bbrc.2005.06.055 15990085 10.1016/j.bbrc.2005.06.055 1:CAS:528:DC%2BD2MXmt1aqsL0%3D (Pubitemid 40978503)
39. Y Liu Y Zhu F Rannou TS Lee K Formentin L Zeng X Yuan N Wang S Chien BM Forman JY Shyy 2004 Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells Circulation 110 1128 1133 10.1161/01.CIR.0000139850.08365.EC 15313948 10.1161/01.CIR.0000139850.08365.EC 1:CAS:528:DC%2BD2cXmvV2gt7o%3D (Pubitemid 39319013)
40. E Mannucci M Monami C Lamanna GF Gensini N Marchionni 2008 Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials Diabetes Obes Metab 10 1221 1238 10.1111/j.1463-1326.2008.00892.x 18505403 10.1111/j.1463-1326.2007.00724.x 1:CAS:528:DC%2BD1MXlvVaqsw%3D%3D
41. T Mazzone PM Meyer SB Feinstein MH Davidson GT Kondos RB D'Agostino Sr A Perez JC Provost SM Haffner 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2572 2581 10.1001/jama.296.21.joc60158 17101640 10.1001/jama.296.21.joc60158 1:CAS:528:DC%2BD28Xht12lsbbM (Pubitemid 44903861)
42. SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 10.1056/NEJMoa072761 17517853 10.1056/NEJMoa072761 1:CAS:528: DC%2BD2sXms1SisrY%3D (Pubitemid 46919772)
43. SE Nissen K Wolski EJ Topol 2005 Effect of Muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus JAMA 294 2581 2586 10.1001/jama.294.20.joc50147 16239637 10.1001/jama.294.20. joc50147 1:CAS:528:DC%2BD2MXht1KisLjJ (Pubitemid 41697247)
44. H Nomura H Yamawaki M Mukohda M Okada Y Hara 2008 Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel J Pharmacol Sci 108 258 265 10.1254/jphs.08117FP 18987433 10.1254/jphs.08117FP 1:CAS:528: DC%2BD1cXhsVKgtLzI
45. G Orasanu O Ziouzenkova PR Devchand V Nehra O Hamdy ES Horton J Plutzky 2008 The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice J Am Coll Cardiol 52 869 881 10.1016/j.jacc.2008.04.055 18755353 10.1016/j.jacc.2008.04.055 1:CAS:528:DC%2BD1cXhtVKju7jF
46. H Oshio T Abe T Onogawa H Ohtsuka T Sato T Ii K Fukase M Muto Y Katayose M Oikawa T Rikiyama S Egawa M Unno 2008 Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines J Gastroenterol 43 538 549 10.1007/s00535-008-2188-3 18648741 10.1007/s00535-008-2188-3 1:CAS:528:DC%2BD1cXoslGlt74%3D
47. CB Patel JA De Lemos KL Wyne DK McGuire 2006 Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism Diab Vasc Dis Res 3 65 71 10.3132/dvdr.2006.016 17058625 10.3132/dvdr.2006.016 (Pubitemid 44638378)
48. C Penna D Mancardi F Tullio P Pagliaro 2008 Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion Basic Res Cardiol 103 368 377 10.1007/s00395-007-0695-7 18188493 10.1007/s00395-007-0695-7
49. P Reyes-Martin S Ramirez-Rubio T Parra-Cid R Bienes-Martinez J Lucio-Cazana 2008 15-Deoxy-delta12, 14-prostaglandin-J(2) up-regulates cyclooxygenase-2 but inhibits prostaglandin-E(2) production through a thiol antioxidant-sensitive mechanism Pharmacol Res 57 344 350 10.1016/j.phrs.2008.03. 007 18456507 10.1016/j.phrs.2008.03.007 1:CAS:528:DC%2BD1cXmvFSiurw%3D
50. J Sakamoto H Kimura S Moriyama H Odaka Y Momose Y Sugiyama H Sawada 2000 Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochem Biophys Res Commun 278 704 711 10.1006/bbrc.2000.3868 11095972 10.1006/bbrc.2000.3868 1:CAS:528:DC%2BD3cXotlalurw%3D
51. H Sato R Bolli GD Rokosh Q Bi S Dai G Shirk XL Tang 2007 The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats Am J Physiol Heart Circ Physiol 293 H2557 H2564 10.1152/ajpheart.00858.2007 17704286 10.1152/ajpheart.00858.2007 1:CAS:528:DC%2BD2sXht1Wlu7%2FP (Pubitemid 47605904)
52. CW Shiau CC Yang SK Kulp KF Chen CS Chen JW Huang CS Chen 2005 Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma Cancer Res 65 1561 1569 10.1158/0008-5472.CAN-04-1677 15735046 10.1158/0008-5472.CAN-04-1677 1:CAS:528:DC%2BD2MXhsFKqtbo%3D (Pubitemid 40270186)
53. A Skyschally P van Caster K Boengler P Gres J Musiolik D Schilawa R Schulz G Heusch 2009 Ischemic postconditioning in pigs: no causal role for RISK activation Circ Res 104 15 18 10.1161/CIRCRESAHA.108.186429 19038864 10.1161/CIRCRESAHA.108.186429 1:CAS:528:DC%2BD1cXhsFSmt7%2FJ
54. A Sugawara A Uruno M Kudo K Matsuda CW Yang S Ito 2010 Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease Endocr J 57 847 852 10.1507/endocrj.K10E-281 20890053 10.1507/endocrj.K10E-281 1:CAS:528:DC%2BC3MXltlWmug%3D%3D
55. H Takano H Hasegawa Y Zou I Komuro 2004 Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases Curr Pharm Des 10 2779 2786 10.2174/1381612043383719 15320743 10.2174/1381612043383719 1:CAS:528:DC%2BD2cXmsVCmsL4%3D (Pubitemid 39137176)
56. F Turturro R Oliver 3rd E Friday I Nissim T Welbourne 2007 Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines Am J Physiol Cell Physiol 292 C1137 C1146 10.1152/ajpcell.00396.2006 17065204 10.1152/ajpcell.00396.2006 1:CAS:528:DC%2BD2sXjsFeqsLs%3D (Pubitemid 46440401)
57. NS Wayman Y Hattori MC McDonald H Mota-Filipe S Cuzzocrea B Pisano PK Chatterjee C Thiemermann 2002 Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size Faseb J 16 1027 1040 10.1096/fj.01-0793com 12087064 10.1096/fj.01-0793com 1:CAS:528:DC%2BD38XltlKitb4%3D (Pubitemid 34753509)
58. AM Wynne MM Mocanu DM Yellon 2005 Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3 K and P42/44MAPK J Cardiovasc Pharmacol 46 817 822 10.1097/01.fjc.0000188365.07635.57 16306807 10.1097/01.fjc.0000188365.07635.57 1:CAS:528:DC%2BD2MXht1Cit7rI (Pubitemid 44378255)
59. L Xu C Han K Lim T Wu 2006 Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells Cancer Res 66 11859 11868 10.1158/0008-5472.CAN- 06-1445 17178883 10.1158/0008-5472.CAN-06-1445 1:CAS:528:DC%2BD28Xhtlagu7rO (Pubitemid 46094198)
60. Y Xu M Gen L Lu J Fox SO Weiss RD Brown D Perlov H Ahmad P Zhu C Greyson CS Long GG Schwartz 2005 PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol 288 H1314 H1323 10.1152/ajpheart.00618.2004 15528232 10.1152/ajpheart.00618.2004 1:CAS:528:DC%2BD2MXisVOjs74%3D (Pubitemid 40270039)
61. S Yasuda H Kobayashi M Iwasa I Kawamura S Sumi B Narentuoya T Yamaki H Ushikoshi K Nishigaki K Nagashima G Takemura T Fujiwara H Fujiwara S Minatoguchi 2009 Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction Am J Physiol Heart Circ Physiol 296 H1558 H1565 10.1152/ajpheart.00712.2008 19286954 10.1152/ajpheart.00712.2008 1:CAS:528:DC%2BD1MXlvFans78%3D
62. Y Ye Z Hu Y Lin C Zhang JR Perez-Polo 2010 Downregulation of microRNA-29 by antisense inhibitors and a PPAR-{gamma} agonist protects against myocardial ischaemia-reperfusion injury Cardiovasc Res 87 535 544 10.1093/cvr/cvq053 20164119 10.1093/cvr/cvq053 1:CAS:528:DC%2BC3cXptVyltbo%3D
63. Y Ye KT Keyes C Zhang JR Perez-Polo Y Lin Y Birnbaum 2010 The myocardial infarct size limiting effects of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA Am J Physiol Heart Circ Physiol 298 H1454 H1465 10.1152/ajpheart.00867.2009 20207816 10.1152/ajpheart.00867.2009 1:CAS:528:DC%2BC3cXmt1Kmurk%3D
64. Y Ye Y Lin S Atar MH Huang JR Perez-Polo BF Uretsky Y Birnbaum 2006 Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions Am J Physiol Heart Circ Physiol 291 H1158 H1169 10.1152/ajpheart.00096.2006 16603698 10.1152/ajpheart.00096.2006 1:CAS:528:DC%2BD28XhtVSksrjO (Pubitemid 44343659)
65. Y Ye Y Lin S Manickavasagam JR Perez-Polo BC Tieu Y Birnbaum 2008 Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice Am J Physiol Heart Circ Physiol 295 H2436 H2446 10.1152/ajpheart.00690.2008 18931027 10.1152/ajpheart.00690.2008 1:CAS:528:DC%2BD1cXhsFSntbvI
66. Y Ye Y Lin JR Perez-Polo Y Birnbaum 2008 Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone Cardiovasc Drugs Ther 22 429 436 10.1007/s10557-008-6138-3 18825491 10.1007/s10557-008- 6138-3 1:CAS:528:DC%2BD1cXhtlGhsb%2FK